All In Biotech

Drug Trial Radar · NCT06321965

Characterization of New Phenotypes of Patients With Spinal Muscular Atrophy Treated With SMN Restoring Therapy

Last checked: Nov 20, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 24, 2024

Primary completion

Jan 24, 2029

Study completion Jan 24, 2029

Sponsor

Lead sponsor
Hospices Civils de LyonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 0 years, up to 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

With the advent of new treatments for ASI, new phenotypes are emerging. The investigators propose to describe these new phenotypes by prospectively following children with ASI of all types treated with TRS and aged under 16 for 2 years. The investigators also propose to evaluate potential assessment tools to determine whether they are relevant for monitoring this population, either routinely or for future clinical trials. The investigators also aim to collect the total costs associated with ASI in order to propose a first prospective medico-economic study in France.

Conditions

  • Spinal Muscular Atrophy

Interventions

  • evaluation of muscle functionOther

    Myogrip (≥ 6 years): precise dynamometric measurement of gripping force, measuring force in Newton up to 90kg with 0.01kg resolution. It's evaluated at D0, M6, M12, M18, and M24 Myopinch (≥ 6 years) : measure thumb-index force up to 15 kg with a resolution of 0.001 kg using a precision sensor equipped with two steel distance blades. It's evaluated at D0, M6, M12, M18, and M24

  • First-line cognitive assessmentOther

    Vineland-II (All patients) : is a scale for assessing adaptive behaviors. will be carried out during the telephone call at M1/V2. All tests are evaluated at D0, and M18 : Bayley-4 language part (\< 42 months) PVSE (≥ 4 years) CELF-5 (≥ 5 years) Conners-3 (≥ 6 years) AQ (≥ 4 years), EQ (≥ 11 years) M-CHAT-R (\< 4 years) : SRS-2 (≥ 2 years)

  • second-line cognitive assessmentOther

    In the event of positive cognitive screening at D0 or M18, a second-line cognitive assessment will be carried out at a subsequent visit. A list of tests is proposed below, but will be adapted according to the tests available at each center. * EVALO BB (0-2 years) or EVALO (2-6 years) or full CELF-5 (5-18 years) following positive screening in the communication domain of first-line tests (Vineland II communication domain, Bayley 4, CELF-5 pragmatic profile) * FEE and DSM-5 diagnostic criteria for ADHD (from age 6 only) following positive screening in the attention and executive functions domain of first-line tests (Conners 3, BRIEF) * M-CHAT-R/F (\< 4 years) or SCQ (≥ 4 years) and ADOS-2 (≥ 12 years) following a positive screening in the area of social cognition and autistic traits on first-line tests (Vineland II, M-CHAT-R, SRS-2, EQ, AQ).

  • Cardiac evaluationOther

    All tests are evaluated at D0, M12, and M24 : Electrocardiogram (ECG) : This examination will be carried out in accordance with the 12 leads recording the following parameters: verification of sinus rhythm, P wave, PR interval, QRS complex (interval), ST segment, T wave, QT complex, heart rate. Cardiac ultrasound: Non-invasive ultrasound will focus on the following parameters measured from 2-dimensional images, to look for cardiomyopathy and/or structural abnormality: * end-diastolic/end-systolic diameter/left ventricular ejection fraction * Septal wall thickness / left ventricular posterior wall * Fractional shortening 24-hour Holter-ECG : This examination consists of a continuous test recording the heart rhythm for 24 hours.

  • MRIRadiation

    Cerebral MRI : Performed at D0, only for patients with ASI type 1 ≥ 6 years, or younger patients for whom the investigator considers that the examination can be performed without sedation or general anesthesia. It will include sequences: * 3D T1, gradient echo, 1.1 mm voxel, sagittal acquisition * axial T2, spin-echo, slice thickness 4 mm * 3D FLAIR, spin-echo, 1 mm voxel, sagittal acquisition Muscular MRI: performed at V1/J0, and V6/M24. The examination will include water-fat imaging (Dixon) in full-body, 3D mode, with proton density weighting and millimeter resolution.

  • Assessment of activity and muscle fatigueOther

    Syde® : evaluated at D0, M6, M12, M24. Patients aged 2 and over will receive the Syde® wearable device to collect their daily activities. Muscular endurance tests (≥ 6 years) : evaluated at D0, M12, M24 ( only one of 3 tests based on motor function level) oESNHPT : In this test, patients are asked to walk a 10-meter path. oESBBT : In this test, patients have to move 10 blocks over a partition. oESWT: In this test, patients must repeatedly place and remove 9 sticks in 9 holes. PedsQL Fatigue (≥ 2 years): evaluated at D0, M12, M24. Scale designed to measure fatigue in patients with acute and chronic conditions, as well as in healthy school and community populations. Fatigue rating scale (≥ 6 years): evaluated at D0, M12, M24. The fatigue assessment scale has 11 numerical points ranging from 0 to 10. The patient is asked to give a rating that best reflects his or her perception of fatigue at that particular moment.

  • Assessment of bulbar functionOther

    DDD-pNMD (≥ 2 years) : evaluated at D0, M6, M12, M18, and M24, is a list of 9 questions used by doctors to screen for dysphagia and dysarthria. NdSSS (All Patients) : evaluated at D0, M6, M12, M18, and M24, is an 8-level scale for assessing swallowing. TOMASS-c : (≥ 4 years of age, in patients able to eat solids safely, after assessment of the risk of a false route by the speech therapist): this is a score designed to assess mastication when eating a cracker. Age-dependent standards exist for different types of cracker. \- Fluid intake test (\> 110 cm, in patients able to drink a liquid safely, after assessment of the risk of a false route by the speech therapist): swallowing limit.

  • Evaluation of body composition and metabolismOther

    Food survey : The dietary survey questionnaire will be sent to parents at D0 and M18. Parents will be asked to complete it for 3 days before the M6 and M24. Bioelectrical impedancemetry: Evaluated at M6 and M24. Renal ultrasound: Evaluated at M6, is a non-invasive examination that analyzes the appearance of the kidney and urinary tract. Dual-energy X-ray absorptiometry (DXA) : Evaluated at M6, it measures body composition using spectral imaging, including fat mass, lean mass and bone mineral density. Fibroscan : Evaluated at M6 and M24. This examination uses pulse elastography to measure liver elasticity, which provides information on the presence of hepatic fibrosis, and sound attenuation, which provides information on the presence of liver fat overload. Indirect calorimetry : Evaluated at M6. This device enables precise measurement of Resting Energy Expenditure , Respiratory Quotient and metabolic substrate oxidation.

  • QuestionnairesOther

    SMAIS : The questionnaire has been developed specifically for ASI. At D0, M6, M12, M18 and M24. HUI2 : specializes in preference-based measures of health-related quality of life. At D0, M6, M12, M18 and M24. Peds QL : is a modular instrument designed to measure health-related quality of life and disease-specific symptoms. At D0, M6, M12, M18 and M24. Neuromuscular module : 17 disease-related items. It is evaluated at D0, M6, M12, M18 and M24. Family impact module : It measures parents' reported physical, emotional, social and cognitive functioning, communication and concerns. At D0, M12, and M24. ASI cost questionnaire: At visit 1 (D0): This questionnaire, completed by the parents, includes information on occupation, parents' working hours and any reduction in them due to the child's pathology, the number of working days missed by the parents or school days missed by the child, and disability-related costs.

  • BiocollectionBiological

    A blood bio collection (optional) will be offered to patients at D0, M6 , M12, M18, M24. Patients receiving intrathecal injections will also be offered the opportunity to participate in a CSF (cerebrospinal fluid) biocollection (optional).

  • Skinfold measurementOther

    The tricipital point should be marked on the posterior aspect of the arm, on the midline of the tricipital muscle, midway between the acromion and the radius. At D0, M6, M12, M18 and M24

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Markers of disease progression and description of different phenotypes, at : muscular and functionalTime frame: Every 6 months from inclusion (Day 0, Month6, Month12, Month18, Month24)
  2. Markers of disease progression and description of different phenotypes, at : muscular and functionalTime frame: Every 6 months from inclusion (Day 0, Month 6, Month 12, Month 18, Month 24)
  3. Markers of disease progression and description of different phenotypes, at : muscular and functionalTime frame: Every 6 months from inclusion (Day 0, Month 6, Month 12, Month 18, Month 24)
  4. Markers of disease progression and description of different phenotypes, at : muscular and functionalTime frame: Every 6 months from inclusion (Day 0, Month 6, Month 12, Month 18, Month 24)
  5. Markers of disease progression and description of different phenotypes, at : muscular and functionalTime frame: Every 6 months from inclusion (Day 0, Month 6, Month 12, Month 18, Month 24)
  6. Markers of disease progression and description of different phenotypes, at : FatigueTime frame: Syde: At Day 0, Month 6, Month 12 and Month 24
  7. Markers of disease progression and description of different phenotypes, at : FatigueTime frame: Endurance test (≥ 6 years)
  8. Markers of disease progression and description of different phenotypes, at : FatigueTime frame: at Day 0, Month 12 and Month 24
  9. Markers of disease progression and description of different phenotypes, at Orthopaedic levelTime frame: Joint amplitudes at Day 0, Month 6, Month 12 and Month 24
  10. Markers of disease progression and description of different phenotypes, at Orthopaedic levelTime frame: Clinic and spinal radiography at Day 0, Month 12,Month 18, Month 24
  11. Markers of disease progression and description of different phenotypes, at Orthopaedic levelTime frame: at Day 0, Month 24+/- Month 6, Month 12, Month 18
  12. Markers of disease progression and description of different phenotypes, at the cognitive level: Vineland-IITime frame: At Month 1
  13. Markers of disease progression and description of different phenotypes, at the cognitive level: Bayley-4Time frame: At Day 0 and Month 18
  14. Markers of disease progression and description of different phenotypes, at the cognitive level: BRIEF (Behavioral Rating Inventory of Executive Function)Time frame: At Day 0 and Month 18
  15. Markers of disease progression and description of different phenotypes, at the cognitive level: Conners-3Time frame: At Day 0 and Month 18
  16. Markers of disease progression and description of different phenotypes, at the cognitive level: CELF-5 (Language and communication assessment battery)Time frame: At Day 0 and Month 18
  17. Markers of disease progression and description of different phenotypes, at the cognitive level: EQ (Empathy quotient), AQ (Autism Quotient)Time frame: At Day 0 and Month 18
  18. Markers of disease progression and description of different phenotypes, at the cognitive level: M-CHAT-R (Modified Checklist for Autism in Toddlers)Time frame: At Day 0 and Month 18
  19. Markers of disease progression and description of different phenotypes, at the cognitive level: SRS-2 (Social Responsiveness Scale, Second Edition)Time frame: At Day 0 and Month 18
  20. Markers of disease progression and description of different phenotypes, at the cognitive level: PVSE (Basic visuo-spatial perception)Time frame: At Day 0 and Month 18
  21. Markers of disease progression and description of different phenotypes, at the brain levelTime frame: At Day 0
  22. Markers of disease progression and description of different phenotypes, at Cardiology levelTime frame: At Day 0 +/- Month 12, Month 24
  23. Markers of disease progression and description of different phenotypes, at metabolic level : Anthropometric measurement trendsTime frame: Anthropometric measurements at Day 0, Month 6, Month 12, Month 18, Month 24
  24. Markers of disease progression and description of different phenotypes, at metabolic level :Time frame: Food survey at Month 6, Month 24
  25. Markers of disease progression and description of different phenotypes, at metabolic level : fracturesTime frame: at Day 0, Month 6, Month 12, Month 18, Month 24
  26. Markers of disease progression and description of different phenotypes, at metabolic level : renal ultrasoundTime frame: at Month 6
  27. Markers of disease progression and description of different phenotypes, at metabolic level : Absorptiometry (DXA)Time frame: at Month 6
  28. Markers of disease progression and description of different phenotypes, at metabolic level: CalorimetryTime frame: at Month 6
  29. Markers of disease progression and description of different phenotypes, at metabolic level : ImpedancemetryTime frame: at Month 6 and Month 24
  30. Markers of disease progression and description of different phenotypes, at metabolic level : FibroscanTime frame: At Month 6 and Month 24
  31. Markers of disease progression and description of different phenotypes, at biological analysisTime frame: At Day 0, Month 6, Month 12, Month 18, Month 24
  32. Markers of disease progression and description of different phenotypes, at In terms of quality of life and autonomyTime frame: PedsQL family impact at Day 0, Month 12, Month 24
  33. Markers of disease progression and description of different phenotypes, at In terms of quality of life and autonomyTime frame: HUI-2, generic PedsQL and neuromuscular module at Day 0, Month 6, Month 12, Month 18 and Month 24
  34. Markers of disease progression and description of different phenotypes, at respiratory level : Chest/head circumference ratio (PT/PC ratio) (up to 3 years)Time frame: at Day 0, Month 6, Month 12, Month 18 and Month 24
  35. Markers of disease progression and description of different phenotypes, at respiratory level : Chest/head circumference ratio (PT/PC ratio)Time frame: at Day 0, Month 6, Month 12, Month 18 and Month 24
  36. Markers of disease progression and description of different phenotypes, at respiratory level : O2 saturation and nocturnal TcPCO2Time frame: at Day 0, Month 12, Month 24
  37. Markers of disease progression and description of different phenotypes, at respiratory level: Respiratory function tests (≥ 6 years)Time frame: at Day 0, Month 12, Month 24
  38. Markers of disease progression at respiratory levelTime frame: points (Day 0, between Day 0-Month 12, between Month 12 and Month 24)
  39. Markers of disease progression and description of different phenotypes, at bulbar level (Evaluation of dysphagia and dysarthria): DDD-pNMD (Diagnostic list for Dysphagia and Dysarthria in pediatric NeuroMuscular Disorders)Time frame: At Day 0, Month 6, Month 12, Month 18, Month 24
  40. Markers of disease progression and description of different phenotypes, at bulbar level (Evaluation of dysphagia and dysarthria): NdSSS (Neuromuscular Disease Swallowing Status Scale).Time frame: At Day 0, Month 6, Month 12, Month 18, Month 24
  41. Markers of disease progression and description of different phenotypes, at the level of Characteristics at inclusion: age of patientTime frame: At Day 0
  42. Markers of disease progression and description of different phenotypes, at the level of Characteristics at inclusion : patient genderTime frame: At Day 0
  43. Markers of disease progression and description of different phenotypes, at the level of Characteristics at inclusion: SMA TYPETime frame: At Day 0
  44. Markers of disease progression and description of different phenotypes, at the level of Characteristics at inclusion: number of copyTime frame: At Day 0
  45. Markers of disease progression and description of different phenotypes, at the level of Characteristics at inclusion: treatmentTime frame: At Day 0

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • CHRU of Brest

    Brest, France · Not yet recruiting

  • Pediatric Neurology and Resuscitation Raymond-Poincare Hospital

    Garche, France · Not yet recruiting

  • Pediatric Neurology Swynghedauw Hospital

    Lille, France · Not yet recruiting

  • Marseille University Hospital - Timone Hospital Department of Pediatric Neurology - Specialized Pediatrics and Child Medicine

    Marseille, France · Not yet recruiting

  • I-Motion Pediatric Clinical Trial Platform Armand Trousseau Hospital

    Paris, France · Not yet recruiting

  • Hautepierre Hospital - Mother and Child Hospital

    Strasbourg, France · Not yet recruiting

  • Department of Pediatrics - Neurology and Infectious Diseases Toulouse University Hospital - Children's Hospital

    Toulouse, France · Not yet recruiting

  • Pediatric Rehabilitation Service - L'Escale Mother and Child Hospital

    Bron, Rhone, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.